Cardiovascular safety in the treatment of diabetes mellitus type 2: focus on alogliptin
https://doi.org/10.21518/2079-701X-2016-3-38-47
Abstract
In the context of cardiac safety, the article discusses the prospects and benefits of a representatives of the DPP-4 inhibitors class - alogliptin (Vipidiya) for the management of hyperglycemia in patients with diabetes type 2 (T2DM).
About the Authors
A. L. Terekhova
First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Russian Federation
N. A. Petunina
First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Russian Federation
References
1. http://www.atse.org.au/Documents/briefings/ diabetes-perfect-storm-may-2010.pdf
2. IDF Diabetes Atlas, 6th edition [Электронный ресурс] - IDF. 2013. Режим доступа: https:// www.idf.org/sites/default/files/EN_6E_Atlas_ Full_0.pdf
3. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract., 2010, 87(1): 4-14.
4. One adult in ten will have diabetes by 2030 [Электронный ресурс]. International Diabetes Federation., 2011. Режим доступа: http//www. idf.org/media-events/press-releases/2011/dia-betes-atlas-5th-edition.
5. Дедов И.И., Шестакова М.В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 7-е изд., 2015.
6. Warram J, Kopczynski J, Janka H, Krolewski A. Epidemiology of non-insulindependent diabetes mellitus and its macrovascular complications: a basis for the Development of Cost-Effective Programs. Endocrinol. Metabol. Clin., 1997, 26: 165-188.
7. Дедов И.И. Диабет как фактор риска сердечно-сосудистых заболеваний. Сердечная недостаточность, 2003, 1: 12-15.
8. American Diabetes Association; National Heart, Lung and Blood Institute; Juvenile Diabetes Foundation International; National Institute of Diabetes and Kidney Disease; American Heart Association. Diabetes mellitus: a major risk factor for cardiovascular disease. Circulation, 1999, 100: 1132-1133.
9. Aronson Doron, Elliot J. Rayfield, James H. Chesebro Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med., 1997, 126(4): 296-306.
10. Барбараш ОЛ., Осокина А.В., Каретникова В.Н. и др. Прогнозирование сердечно-сосудистых осложнений у больных инфарктом миокарда и сахарным диабетом. Роль CD40-лиганда. Медицина в Кузбассе, 2010, 2: 11-16.
11. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: opidemiology, pathophysiology and management. J. Am. Med. Assoc., 2002, 287: 2570-2581.
12. Шестакова М.В. Сахарный диабет и артериальная гипертензия. Руководство по артериальной гипертонии. Под ред. Чазова Е.И., Чазовой И.Е. М.: Медиа Медика, 2005. С. 415-433.
13. Карпов Ю.А. Контроль артериального давления как самая эффективная профилактика сердечно-сосудистых осложнений у больных сахарным диабетом 2 типа. Сахарный диабет, 2009, 2: 10-13.
14. Кисляк О.А., Мышляева Т.О. Контроль артериального давления и профилактика сердечнососудистых осложнений при сахарном диабете II типа: результаты исследования ADVANCE. Лечебное дело, 2008, 1: 38-46.
15. Панова Е.И. Корригируемые и некорригируе-мые факторы неблагоприятного течения и отдаленных исходов инфаркта миокарда у больных сахарным диабетом 2 типа: автореф. дисс. докт. мед. наук: 14.00.05. Н. Новгород, 2009. 255 с.
16. Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, Kereiakes DJ, Topol EJ. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with throm-bolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol., 1993, 21(4): 920-925.
17. Barzilay JI, Kronmal RA, Bittner V, Eaker E, Evans C, Foster ED. Coronary artery disease and coronary artery bypass grafting in diabetic patients aged >65 years (report from the coronary artery surgery study [CASS] registry). Am J Cardiol., 1994, 74(4): 334-339.
18. Всероссийское научное общество кардиологов. Кардиоваскулярная профилактика. Национальные рекомендации [Электронный ресурс]. Российское кардиологическое общество. 2011. Режим доступа: http//www.scardio. ru/content/images/recommendation/nacional-nye_rekomendacii_po_kardiovaskulyarnoy_ profilaktike.pdf.
19. Александров Ан.А., Бондаренко И.З., Кухаренко С.С. и соавт. Сахарный диабет и ишемическая болезнь сердца: поиски решения. Сахарный диабет, 2005, 3: 34-38.
20. Ярек-Мартынова И.Р, Шестакова М.В. Сердечно-сосудистые заболевания у больных сахарным диабетом. Правовые вопросы в здравоохранении, 2010, 1: 46-50.
21. Акчурин Р.С., Власова Э.Е., Мершин К.В. Сахарный диабет и хирургическое лечение ишемической болезни сердца. Вестник Российской академии медицинских наук, 2012, 1: 14-19.
22. Christopher LL Morgan, Craig J. Currie, John R. Peters Relationship between Diabetes and Mortality. Diabetes Care, 2000, 23: 1103-1107.
23. Дедов И.И., Александров Ан.А. Проблемы острого инфаркта миокарда у больных сахарным диабетом: эхо Мюнхена. Сахарный диабет, 2008, 4: 4-10.
24. Kjaergaard SC, Hansen HH, Fog L, Bulow I, Christensen PD Inhospital outcome for diabetic patients with acute myocardial infarction in the thrombolytic era. Scand. Cardiovasc. J., 1999, 33(3): 166-170.
25. Рудакова Л.Е., Беляева Ю.Б., Рахматуллов Ф.К. и соавт. Особенности течения фатального инфаркта миокарда у больных сахарным диабетом 2 типа. Медицинские науки. Клиническая медицина, 2011, 2: 117-127.
26. Александров А.А., Кухаренко С.С., Бондаренко И.З. и соавт. Ишемическая болезнь сердца и сахарный диабет: алгоритм диагностики, профилактики и лечения: пособие для врачей. Под общ. ред. И.И. Дедова. М.: Перспектива, 2007. 24 с.
27. Malmberg K, Ryden L, Wedel H, BirkeLand K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, MacLeod K, Laakso M, Torp-Pedersen C, Waldenstrom A. for the DIGAMI 2 Investigators. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on morbidity and mortality. Eur Heart J., 2005, 26(7): 650-661.
28. Мареев В.Ю. и соавт. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Сердечная недостаточность, 2010, 11(1): 3-63.
29. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factor. DiabetesСare, 2001, 24(9): 1614-1619.
30. Fchtenbusch M, Standl E, Otter W, Hummel M. Diabetes mellitus and heart failure. MMW. Fortschr. Med., 2007, 149(37): 41-44.
31. Мареев В.Ю., Беленков Ю.Н., Масенко В.П. и соавт. Влияние тяжести хронической сердечной недостаточности на течение сопутствующего сахарного диабета 2-го типа. Тер. арх., 2009, 9: 52-57.
32. Vaur L, Gueret P, Lievre M et al. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DI-ABHYCAR (type 2 DIABetes, Hypertension, Cardiovascular Events and Ramipril) study. Diabetes Care, 2003, 26(3): 855-860.
33. Какорин С.В., Тулякова Э.В., Воронкова К.В., Мкртумян А.М. Острое нарушение мозгового кровообращения у больных сахарным диабетом 2 типа. Сахарный диабет, 2013, 1: 63-70.
34. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke. A population perspective. Diabetologia, 1995, 38(9): 1061-1068.
35. Karapanayiotides T, Piechowski-Jozwiak B, van Melle G, Bogousslavsky J, Devuyst G. Stroke patterns, etiology, and prognosis in patients with diabetes mellitus. Neurology, 2004, 62(9): 1558-1562.
36. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ. Risk of dementia among persons with diabetes melli-tus: a population-based cohort study. Am J Epidemiol., 1997, 145(4): 301-308.
37. Шестакова М.В., Чугунова Л.А., Тарасов Е.В. Инсульт и сахарный диабет 2-го типа. Возможности профилактики. Тер. арх., 2006, 10: 21-26.
38. Галстян Г.Р. Поражения нижних конечностей у больных сахарным диабетом. Consilium Medicum, 2006, 8(9): 12-18.
39. Гордеев А.В. Поражение почек у пожилых при сахарном диабете 2 типа: автореферат дисс. д-ра мед. наук: 14.01.29. М., 2002, 44 с.
40. Шамхалова М.Ш. Патология почек у больных с сахарным диабетом 2 типа: сосудистые, токсические и гормональные аспекты: автореф. дисс. доктора мед. наук: 14.01.02. М., 2008. 48 с.
41. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med., 1993, 329: 977-986.
42. UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascu-lar and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 1998, 317: 703-713.
43. Edward W Gregg, Yanfeng Li, Jing Wang, Nilka Rios Burrows et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med., 2014, 370: 1514-1523. DOI: 10.1056/NEJMoa1310799.
44. American Diabetes Association, Standards of Medical Care in Diabetes-2015. Diabetes Care, 2015, 38(Supp. 1): 1-94.
45. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015, 38: 140-149. doi: 10.2337/dc14-2441
46. Cyrus V Desouza, Geremia B Bolli, Vivian Fonseca. Hypoglycemia, diabetes and cardiovascular events, Diabetes Care, 2010, 33(6): 1389-1394.
47. Food and Drug Administration, Center for Drug Evaluation and Research Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type-2 diabetes - 2008. Available at: http//www.fda. gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM071627.pdf.
48. Дедов И.И., Шестакова М.В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 6-е изд., 2013.
49. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998, 352(9131): 854-865.
50. Roussel R, Travert F, Pasquet B et al. Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med., 2010, 170(21): 1892-1899.
51. McAlister FA, Eurich DT, Majumdar SR, Johnson JA. The risk of heart failure in patients with type 2 diabetes treated with oral agent mono-therapy. Eur J Heart Fail., 2008, 10(7): 703-708.
52. American Diabetes Association Standards of Medical Care in Diabetes-2014. Diabetes Care, 2014, 37(1): S14-S80.
53. Carlsen SM, Rossvoll O, Bjerve KS, Flling I. Metformin improves blood lipid pattern in nonpatients with diabetes with coronary heart disease. J Intern Med., 1996, 239(3): 227-233.
54. Pedersen SD. Impact of newer medications for Type 2 diabetes on body weight. Curr Obes Rep., 2013, 2(2): 134-141.
55. Garber AJ, Abrahamson MJ, Barzilay JI et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract., 2013, 19(2): 327-336.
56. Sirtori CR, Tremoli E, Sirtori M, Conti F, Paoletti R. Treatment of hypertriglyceridemia with met-formin. Effectiveness and analysis of results. Atherosclerosis, 1977, 26(4): 583-592.
57. Hollenbeck CB, Johnston P, Varasteh BB, Chen YD, Reaven GM. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria. Diabete Metab., 1991, 17(5): 483-489.
58. Бутрова С.А., Елисеева А.Ю., Ильин А.В. Эффективность метформина и больных с метаболическим синдромом и неалкогольной жировой болезнью печени. Ожирение и метаболизм, 2008, 2(15): 17-21.
59. Marchesini G, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic ste-atohepatitis. The Lancet, 2001, 4: 893-894.
60. Nair S, Diehl A, Wiseman M. Metformin in the triement of non- alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther., 2004, 20: 23-8.
61. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig., 2010, 1: 8-23.
62. Cox ME, Rowell J, Corsino L, Green JB. Dipeptidyl peptidase-4 inhibitors in the management of type diabetes: safety, tolerability and efficacy. Drug Healthc Patient Saf., 2010, 2: 7-19.
63. Balakumar P, Dhanaraj SA. Cardiovascular plei-otropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials. Cell Signal., 2013, 25(9): 1799-1803.
64. Chrysant SG, Chrysant GS. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Cardiol., 2012, 109(11): 1681-1685.
65. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev., 2012, 33: 187-215.
66. Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res., 2012, 9: 109-116.
67. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin., 2011, 27(Suppl. 3): 57-64.
68. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab., 2013, 15(10): 938-953.
69. Roumie CL, Hung AM, Greevy RA et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med., 2012, 157: 601-610.
70. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med., 2007, 356: 2457-2471.
71. Scirica BM, Bhatt DL, Braunwald E et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med., 2013, 3, 369(14): 1317-1326.
72. White WB, Cannon CP, Heller SR, et al. and the EXAMINE Investigators. Alogliptine after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med, 2013, 369: 1327-1335.
73. Green JB, Bethel MA, Armstrong PW et al. Effect of Sitagliptin on Cardiovascular Outcomes in type diabetes. NEJM, DOI: 10.1056/ NEJMoa1501352.
74. CAROLINA (NCT01243424). Available at: www. clinicaltrials.gov/ct2/show/NCT01243424.
75. Del Prato S, Camisasca RR, Craig Wilson et al. Durability of the efficacy and safety of aloglip-tin compared with glipizide in type 2 diabetes mellitus; a 2-year study. Diab, Obes and Metab., 2014, 16: 1239-1246.
76. Zannad F, Cannon C, Cushman W et al. Alogliptin in patients with type 2 diabetes after acute coronary syndromes: heart failure outcomes and cardiovascular safety in heart failure patients. JACC, 2014, 63(12).
77. Петунина Н.А., Терехова А.Л. Алоглиптин -эффективный и безопасный выбор в терапии сахарного диабета типа 2. Consilium Medicum, 2015, 17(4): 14-19.
78. Dedov I.I., Shestakova M.V. Algorithms of specialized medical care to patients with diabetes. 7th ed., 2015.
79. Dedov I.I. Diabetes is a risk factor for cardiovascular disease. Serdechnaya Nedostatochnost, 2003, 1: 12-15.
80. Barbarash O.L., Osokina A.V., Karetnikova V.N. et al. Predicting cardiovascular complications in patients with myocardial infarction and diabetes. The role of CD40-ligand. Meditsina v Kuzbasse, 2010 2: 11-16.
81. Shestakova M.V. Diabetes and hypertension. A guide on hypertension. Ed. by Chazov E.I., Chazova E.I. М.: Media Medica, 2005. P. 415-433.
82. Karpov Y.A. Control of blood pressure as the most effective prevention of cardiovascular complications in patients with type 2 diabetes. Sakharniy Diabet, 2009, 2: 10-13.
83. Kislyak O.A., Myshlyaeva T.O. Control of blood pressure and prevention of cardiovascular complications in diabetes mellitus type II: results of the ADVANCE study. Lechebnoye Delo, 2008, 1: 38-46.
84. Panova E.I. Corrective and non-corrective factors of unfavorable course and long-term outcomes of myocardial infarction in patients with type 2 diabetes: Abstract of thesis for the degree of MD. 14.00.05. N. Novgorod, 2009. 255 p.
85. All-Russia Society of Cardiologists. Cardiovascular prevention. National guidelines [electronic resource]. Russian Society of Cardiology. 2011. Access: http://www.scardio.ru/content/images/recommendation/nacionalnye_rekomendacii_po_kardiova skulyarnoy_profilaktike.pdf.
86. Alexandrov An.A. Bondarenko I.Z., Kukharenko S.S. et al. Diabetes mellitus and coronary artery disease: search for a solution. Sakharniy Diabet, 2005, 3: 34-38.
87. Yarek-Martynova I.R., Shestakova M.V. Cardiovascular disease in patients with diabetes. Pravovye Voprosy v Zdravookhranenii, 2010, 1: 46-50.
88. Akchurin R.S., Vlasova E.E., Mershin K.V. Diabetes mellitus and surgical treatment of coronary heart disease. Vestnik Rossiyskoy Akademii Meditsinskikh Nauk, 2012, 1: 14-19.
89. Dedov I.I., Aleksandrov An.A. Problems of acute myocardial infarction in patients with diabetes: echo of Munich. Sakharniy Diabet, 2008, 4: 4-10.
90. Rudakova L.E., Belyaeva Yu.B., Rakhmatullov F.K. et al. The specific pattern of fatal myocardial infarction in patients with type 2 diabetes. Medical Sciences. Klinicheskaya Meditsina, 2011, 2: 117-127.
91. Aleksandrov A.A., Kukharenko S.S., Bondarenko I.Z. et al. Coronary heart disease and diabetes: algorithm for diagnosis, prevention and treatment. doctor's manual. Under the gen. ed. of I.I. Dedov. М.: Perspektiva, 2007. 24 p.
92. Mareev V.Y. et al. National recommendations of the All-Russia Society of Cardiologists and Heart Failure Specialists Association for diagnosis and treatment of chronic heart failure (III revision). Serdechnaya Nedostatochnost, 2010, 11(1): 3-63.
93. Mareev V.Y., Belenkov Yu.N., Masenko V.P. et al. Effect of the severity of chronic heart insufficiency on the course of concomitant type 2 diabetes. Ter. Arkhiv, 2009, 9: 52-57.
94. Kakorin S.V., Tulyakova E.V., Voronkova K.V., Mkrtumian A.M. Acute cerebrovascular disorder in patients with diabetes type 2. Sakharniy Diabet, 2013, 1: 63-70.
95. Shestakova M.V., Chugunova L.A., Tarasov E.V. Stroke and type 2 diabetes. Possibilities of prevention. Ter. Arkhiv, 2006, 10: 21-26.
96. Galstyan G.R. Lesions of the lower extremities in patients with diabetes mellitus. Consilium Medicum, 2006, 8(9): 12-18.
97. Gordeev A.V. Renal disease in elderly people with type 2 diabetes: abstract of thesis for the MD degree. 01.14.29. М., 2002, 44 p.
98. Shamkhalova M.S. Renal disease in patients with type 2 diabetes: vascular, toxic and hormonal aspects: Abstract of thesis for the MD degree: 14.01.02. М., 2008. 48 p.
99. Dedov I.I., Shestakova M.V. Algorithms of specialized medical care to patients with diabetes. 6-е изд., 2013.
100. Butrova S.A. Eliseeva A.Y., Ilyin A.V. The efficacy of metformin and patients with metabolic syndrome and nonalcoholic fatty liver disease. Ozhirenie i Metabolizm, 2008, 2(15): 17-21.
101. Petunina NA Terekhova AL Alogliptin - an effective and safe option in the treatment of type 2 diabetes mellitus. Consilium Medicum, 2015, 17(4): 14-19.
Review
For citations:
Terekhova AL, Petunina NA. Cardiovascular safety in the treatment of diabetes mellitus type 2: focus on alogliptin. Meditsinskiy sovet = Medical Council. 2016;(3):38-47. (In Russ.) https://doi.org/10.21518/2079-701X-2016-3-38-47
Views:
665
Email this article 